VCA
PEAR

Verdence Capital Advisors’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Verdence Capital Advisors’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,815
Closed -$28K – 562
2022
Q3 		$28K Buy
+13,815
New +$23.4K ﹤0.01% 514

Other funds holding PEAR

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SGA
SB Global Advisers London, United Kingdom $861M AUM 71.72% 1-Year Est. Return
AV
Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return

Verdence Capital Advisors's PEAR Position: Q4 2022 in Review

Verdence Capital Advisors sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q4 2022, closing a stake of 13,815 shares — an estimated $28K sold.

Verdence Capital Advisors first reported a position in PEAR in Q3 2022 and held it in 1 quarter. The position peaked at $28K in Q3 2022. 64 funds tracked by Wall St. Rank hold PEAR as of Q4 2022.

  • Verdence Capital Advisors reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q4 2022 after selling out during the quarter.
  • Verdence Capital Advisors sold 13,815 Pear Therapeutics, Inc. Class A Common Stock shares in Q4 2022, an estimated $28K.
  • Verdence Capital Advisors first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q3 2022 and held it in 1 quarter.
  • Verdence Capital Advisors's Pear Therapeutics, Inc. Class A Common Stock position peaked at $28K in Q3 2022.
  • 64 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q4 2022.

Based on Verdence Capital Advisors's 13F filing for Q4 2022, filed 23 Jan 2023.